New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
11:16 EDTMNKD, GALT, CYTK, DLLR, APOLOptions with decreasing implied volatility: MNKD GALT CYTK DLLR APOL
News For MNKD;GALT;CYTK;DLLR;APOL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
05:58 EDTMNKDStocks with implied volatility movement; MNKD SHPG
Subscribe for More Information
October 21, 2014
07:34 EDTAPOLApollo Education sees 1Q15 revenue $720M-$730M, consensus $763.70M
Subscribe for More Information
07:33 EDTAPOLApollo Education sees FY15 revenue $2.8B-$2.85B, consensus $2.80B
07:32 EDTAPOLApollo reports Q4 University of Phoenix New Degreed Enrollment down 5.9%
Subscribe for More Information
07:31 EDTAPOLApollo Education reports Q4 EPS from cont. ops. ex-items 34c, consensus 27c
Subscribe for More Information
October 20, 2014
07:37 EDTCYTKCytokinetics completes review results from BENEFIT-ALS regarding tirasemtiv
Cytokinetics provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. The company announced that it has completed its review of results from BENEFIT-ALS and has concluded that effects observed on Slow Vital Capacity in patients treated with tirasemtiv are robust and potentially clinically meaningful. In addition, following consultation with clinical and statistical experts, the company believes that data from BENEFIT-ALS support progression of tirasemtiv to a potential Phase III clinical trial in patients with amyotrophic lateral sclerosis (ALS). The company also announced that it has begun regulatory interactions with the U.S. Food and Drug Administration regarding results from BENEFIT-ALS and has received initial feedback from the FDA. The company believes that effects on SVC could be a Phase III clinical trial endpoint and could support registration of tirasemtiv as a potential treatment for patients with ALS. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015. Cytokinetics has received feedback from the FDA following initial communications regarding tirasemtiv and BENEFIT-ALS. The company believes that the FDA may be willing to consider a potential registration path for tirasemtiv relating to effects on SVC. The company expects to have additional interactions with the FDA and other regulatory authorities. In addition, the company has commenced Phase III readiness activities including designing a potential Phase III clinical trial in order to inform plans, timelines and costs associated with the further development of tirasemtiv.
06:52 EDTMNKDMannKind initiated with a Neutral at Goldman
Target $6.
October 15, 2014
07:07 EDTAPOLFor profit education positive catalysts outweigh negative, says Wells Fargo
Wells Fargo expects for-profit education stocks to benefit from improved hiring trends and a sale by Corinthian of its assets that, according t othe firm ,would set a valuation floor for the sector. The firm continues to believe that the final gainful employment rule will be neutral to positive for the group. Wells favors the option value on the long side for the sector. Publicly traded companies in the space include American Public Education (APEI), Apollo Education (APOL), Bridgepoint Education (BPI), Career Education (CECO), Corinthian Colleges (COCO), DeVry (DV), Grand Canyon (LOPE), ITT Educational (ESI) and Strayer (STRA).
October 13, 2014
07:35 EDTCYTKCytokinetics announces development program update for CK-2127107
Subscribe for More Information
October 9, 2014
12:46 EDTAPOLDoE policy changes a negative for select Education stocks, says Deutsche Bank
Subscribe for More Information
October 8, 2014
05:53 EDTMNKDStocks with implied volatility movement; MNKD AFSI
Stocks with implied volatility movement; MannKind (MNKD) 85, AmTrust Financial (AFSI) 68 according to iVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use